Form 8-K - Current report:
SEC Accession No. 0001628280-25-039883
Filing Date
2025-08-12
Accepted
2025-08-12 16:10:35
Documents
14
Period of Report
2025-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zvra-20250812.htm   iXBRL 8-K 28534
2 EX-99.1 zvra-20250812xex991.htm EX-99.1 154846
6 zevralogo.jpg GRAPHIC 6458
  Complete submission text file 0001628280-25-039883.txt   325953

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zvra-20250812.xsd EX-101.SCH 1785
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zvra-20250812_lab.xml EX-101.LAB 21615
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zvra-20250812_pre.xml EX-101.PRE 12510
16 EXTRACTED XBRL INSTANCE DOCUMENT zvra-20250812_htm.xml XML 2738
Mailing Address 1180 CELEBRATION BOULEVARD, SUITE 103 CELEBRATION FL 34747
Business Address 1180 CELEBRATION BOULEVARD, SUITE 103 CELEBRATION FL 34747 (321) 939-3416
ZEVRA THERAPEUTICS, INC. (Filer) CIK: 0001434647 (see all company filings)

EIN.: 205894398 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36913 | Film No.: 251206786
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)